Time filter

Source Type

Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Albany, NY, May 21, 2017 --( Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027 Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives. The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines. Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA. In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities. Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.html The pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. About Market Research Hub: Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps. MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients. Contact Us 90 State Street, Albany, NY 12207, United States Toll Free: 866-997-4948 (US-Canada) Tel: +1-518-621-2074 Email: press@marketresearchhub.com Albany, NY, May 21, 2017 --( PR.com )-- Tetanus is a frightening disease that has plagued mankind since ancient times. Market Research Hub (MRH) has recently broadcasted a pipeline study done on this bacterial disease and titled as “Tetanus - Pipeline Review, H1 2017.” This study examines comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Moreover, its pipeline analysis by companies involved in its therapeutic development is also mentioned in detail.Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1068027Tetanus, commonly called lockjaw, is a bacterial disease caused by Clostridium bacteria which affects the nervous system. It is contracted through a cut or wound that becomes tainted with tetanus bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, the stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. Unlike many other diseases, tetanus is not commonly diagnosed through laboratory tests. Those infected with this disease will be given medication or vaccines to fight off the bacteria. Treatment includes antibiotics, beta blockers and sedatives.The report initiates with the overview of Tetanus and its therapeutic assessment. Further, the pipeline overview, pipeline companies, and products under development by companies are detailed. As per the report findings, Clostridium tetani is widespread in the environment throughout the world and cannot be eradicated. To reduce the number of cases of tetanus efforts are focused on prevention using vaccination and post-exposure wound care. Vaccination is the finest way to protect against tetanus infection. Due to widespread immunization, tetanus is a rare disease in the U.S. There are four kinds of vaccines used to protect against tetanus, such as Diphtheria and Tetanus (DT) Vaccines; Diphtheria, tetanus and pertussis (DTaP) vaccines; Tetanus and diphtheria (Td) vaccines; Tetanus, diphtheria and pertussis (Tdap) vaccines.Moreover, the pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects. They are as follows Beijing Minhai Biotechnology Co. Ltd., Daiichi Sankyo Company Ltd., Panacea Biotec Ltd., Serum Institute of India Ltd., GlaxoSmithKline Plc, Bharat Biotech International Ltd., Indian Immunologicals Ltd., Prometheon Pharma LLC, Shantha Biotechnics Ltd., Zydus Cadila Healthcare Ltd., Biological E Ltd., Kaketsuken KK, Boryung Pharmaceutical Co. Ltd., Green Cross Corp., LG Chem, Ltd. and Sanofi Pasteur SA.In the later part, the pipeline analysis also features drug profiles for the pipeline products which covers, product descriptive licensing and alliance details, R&D brief and other developmental activities.Browse Full Report With TOC: http://www.marketresearchhub.com/report/tetanus-pipeline-review-h1-2017-report.htmlThe pipeline guide reviews the latest news and press releases related to pipeline therapeutics for Tetanus. Hence, the present guide is a complete repository of information, built using data and information sourced from registered databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.About Market Research Hub:Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.Contact Us90 State Street,Albany, NY 12207,United StatesToll Free: 866-997-4948 (US-Canada)Tel: +1-518-621-2074Email: press@marketresearchhub.com Click here to view the list of recent Press Releases from Market Research Hub


Sumathy K.,Bharat Biotech International Ltd | Ella K.M.,Bharat Biotech International Ltd
Journal of Medical Virology | Year: 2012

The genetic diversity of Chikungunya virus (CHIKV) causing recurring outbreaks in India since 2006 was studied. The 2006 epidemic was caused by a virus strain of the East, Central and South African (ECSA) genotype with 226A in the E1 glycoprotein. The variant strain with E1-A226V mutation caused outbreaks since 2007 in the state of Kerala where Aedes albopictus is the abundant mosquito vector. Molecular epidemiology data since 2007 is scarce from other regions of the country. RT-PCR, sequencing and phylogenetic analyses of CHIKV isolates from the 2009 to 2010 epidemics in the States of Tamil Nadu and Andhra Pradesh placed them in a separate clade within the ECSA lineage. The isolates of the study had 226A in the E1 glycoprotein. The isolates had a novel E1-K211E mutation that was under significant positive selection. E1-211E is highly conserved in the Asian genotype of the virus circulated by Aedes aegypti. Unique mutations in E2 glycoprotein were identified. The two sub-lineages of ECSA genotype circulating in India parallel the abundance of Ae. albopictus and Ae. aegypti. Novel mutations in the envelope glycoproteins suggest adaptive evolution of the virus to local vector abundance. Cross neutralization of the virus isolates from recurring Indian epidemics indicated that no distinct serotypes had evolved. The study has provided insights into the origin, distribution and evolutionary adaptation of the virus to local vector abundance in the region that has reportedly, the highest incidence of CHIKV infection in the world. © 2011 Wiley Periodicals, Inc.


Trademark
Bharat Biotech International Ltd | Date: 2016-02-09

Vaccine preparations.


Trademark
Bharat Biotech International Ltd | Date: 2016-02-09

Vaccine preparations.


Patent
Bharat Biotech International Ltd | Date: 2012-01-03

The invention provides a stable immunogenic composition for prevention and prophylaxis of infections caused by rota virus, poliomyelitis virus, Haemophilius influenza, Hepatitis B, Corynebacterium diphtheriae, Clostridium tetani, Bordatella pertusis (acellular) in a single combined vaccine. The invention also provides for a bivalent immunogenic composition against rota virus and polio virus. The process of making such compositions of the multivalent antigens are also disclosed. The present invention also relates to the production and use of such vaccines for prophylaxis against the infections mentioned above.


Patent
Bharat Biotech International Ltd | Date: 2013-04-23

Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration.


Patent
BHARAT BIOTECH INTERNATIONAL Ltd | Date: 2010-07-14

A synergistic pharmaceutical composition for the preparation of topical formulations for use in prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers, diabetic foot ulcers and other skin diseases is provided. The composition may include one or more synergistically active ingredients and one or more inactive ingredients. The synergistically active ingredients may include Recombinant Human Epidermal Growth Factor (rh-EGF) (REGEN-D of Bharat Biotech International Limited) and/or Platelet Derived Growth Factor (rh-PDGF-BB), silver sulfadiazine (SSD) and chlorhexidine gluconate (CHG). One or more inactive ingredients may comprise carriers, preservatives, emulsifiers, skin emollients and soothers and one or more other constituents.


Patent
Bharat Biotech International Ltd | Date: 2016-07-18

The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.


Patent
Bharat Biotech International Ltd | Date: 2013-05-09

Vaccine combinations which comprise at least two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of preparing the vaccine combinations are disclosed. Nucleic acids encoding the antigens, as well as methods for their production and use are provided.


Patent
BHARAT BIOTECH INTERNATIONAL Ltd | Date: 2010-01-25

Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children.

Loading Bharat Biotech International Ltd. collaborators
Loading Bharat Biotech International Ltd. collaborators